MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?

  • Cardiovascular Research Unit
February 11, 2015 By:
  • Devaux Y
  • Stammet P
  • Friberg H
  • Hassager C
  • Kuiper MA
  • Wise MP
  • Nielsen N
  • Biomarker subcommittee of the T. T. M. trial.

Despite advances in resuscitation medicine, including target temperature management as part of post-cardiac arrest care, many patients will have a poor neurological outcome, most often resulting in death. It is a commonly held belief that the ability to prognosticate outcome at an early stage after cardiac arrest would allow subsequent health care delivery to be tailored to individual patients. However, currently available predictive methods and biomarkers lack sufficient accuracy and therefore cannot be generally recommended in clinical practice. MicroRNAs have recently emerged as potential biomarkers of cardiovascular diseases. While the biomarker value of microRNAs for myocardial infarction or heart failure has been extensively studied, less attention has been devoted to their prognostic value after cardiac arrest. This review highlights the recent discoveries suggesting that microRNAs may be useful both to predict outcome and to treat patients after cardiac arrest.

2015 Feb. Crit Care.19(1):54.
Other information